Overview of Femydrol

Quick Facts

Property	Description
Active ingredient	Estradiol and Medroxyprogesterone
Form	Solution for injection (Aqueous suspension)
Pharmacological class	Sex hormone combinations (Systemic Contraceptive)
Common use	Prevention of pregnancy (Birth Control)
Origin	Synthetic steroid hormone derivatives

What Type of Medicine is Femydrol?

Femydrol is a specialized, prescription-only combined hormonal preparation used for systemic contraception, with the singular primary purpose of preventing pregnancy. This medication belongs to the pharmacological class of sex hormone combinations, specifically operating as an estrogen-progestogen combination. The combination of these two types of sex hormones provides cycle suppression through established pharmacological actions. This establishes Femydrol as a method designed to provide birth control through systemic hormonal regulation.

Composition and Form: Injectable Long-Acting Contraception

The composition of Femydrol is defined by the inclusion of two key synthetic steroid compounds: the estrogen Estradiol and the progestogen Medroxyprogesterone. These components, derived from natural hormone structures, define the drug's origin as a synthetic steroid. Unlike daily oral pills, Femydrol is characteristically supplied as a sterile solution for injection, most frequently an aqueous suspension, which requires a deep intramuscular injection for its route of administration. This difference in form is a key distinguishing factor, positioning it as a long-acting method compared to daily oral preparations.

Core Function: Combined Contraceptive Action

The core function of Femydrol provides contraceptive efficacy by relying on the multi-target actions of both hormones. The primary action involves the combined hormones working together to suppress the necessary signals required for the release of an egg, thereby preventing ovulation. This mechanism is a well-established process in hormonal contraception. The combined nature of the drug confirms that it aims to provide systemic contraception by creating multiple barriers to conception, including the thickening of cervical mucus and the alteration of the uterine lining.

What side effects are possible with Femydrol?

Possible Side Effects and Safety Information

The safety profile for this combined hormonal injection, which contains Estradiol and Medroxyprogesterone, is structured by government regulatory documents based on established frequency classifications and affected physiological systems.

Frequency-Classified Adverse Reactions

Adverse reactions are organized into System-Organ Classes (SOC) in official labeling. Very common effects (those affecting more than 1 in 10 users) primarily include changes in menstrual patterns, such as irregular bleeding, spotting, or the onset of amenorrhea, and weight gain.

Common effects (affecting 1 to 10 in 100 users) typically involve the Nervous System, with reactions such as headache, dizziness, and nervousness, as well as effects like breast tenderness and abdominal discomfort.

Serious Adverse Reactions and Safety Constraints

The official labeling documents several safety constraints and serious adverse reactions. The use of this injection is associated with a Loss of Bone Mineral Density (BMD), which is a recognized risk that may increase with prolonged duration of exposure. For this reason, continuous use for longer than 2 years is generally not recommended unless other contraceptive methods are deemed inadequate.

Documented serious risks also include the potential for thromboembolic events, such as Deep Vein Thrombosis, Pulmonary Embolism, and stroke, as well as the risk of ectopic pregnancy. Use is officially restricted in patients with a history of thromboembolic disorders, known or suspected breast malignancy, significant liver disease, and undiagnosed vaginal bleeding. Safety information is of particular concern for adolescents due to the critical period of bone accretion.

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Femydrol (Estradiol and Medroxyprogesterone) is associated with documented clinical manifestations that are typically mild and self-limiting. The official regulatory profile lists key manifestations, including general symptoms such as nausea, vomiting, dizziness, and abdominal pain. Other common signs of hormonal overexposure are breast tenderness and a feeling of drowsiness or fatigue. An important physiological consequence explicitly documented in the regulatory text is the occurrence of withdrawal bleeding, involving irregular vaginal bleeding.

The regulatory documents explicitly mandate that users seek immediate medical attention or contact emergency services immediately if an overdosage is suspected or confirmed. While the general risks of hormonal therapy are noted elsewhere, severe or life-threatening outcomes are not explicitly listed as acute presentations of overdose in the regulatory sections.

The official regulatory profile confirms that no specific antidote is known for this hormonal combination. Therefore, the mandatory management procedure consists solely of discontinuation of Femydrol therapy at the time of suspected overdose and the institution of appropriate symptomatic and supportive care, as directed by a healthcare professional. There are no explicitly documented population-specific variations or mandatory hospital monitoring requirements for acute overdose in the prescribing information.

Therapeutic Uses of Femydrol

Main Uses and Therapeutic Intent

Femydrol is a pharmacological intervention primarily utilized in the management of hormone-dependent conditions in women. It belongs to a class of medications designed to modulate hormonal pathways, specifically targeting imbalances that contribute to gynecological and reproductive health disorders.

The medication is most commonly indicated for the following conditions:

Endometriosis: Femydrol is used to manage the symptoms and progression of endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterine cavity. By suppressing specific hormonal signals, it helps reduce the proliferation of this ectopic tissue.
Uterine Fibroids: It is employed to reduce the size of noncancerous growths in the uterus (leiomyomas) and to alleviate the associated symptoms, such as heavy menstrual bleeding and pelvic pressure.
Infertility Protocols: In the context of assisted reproductive technology (ART), Femydrol may be used to control the timing of ovulation or to prepare the body for controlled ovarian stimulation.

Benefits and Clinical Impact

The therapeutic goal of Femydrol is to restore physiological balance and improve the patient's quality of life by addressing the underlying hormonal drivers of their condition.

Symptom Management

One of the primary benefits is the reduction of chronic pelvic pain and dysmenorrhea (painful periods) associated with endometriosis and fibroids. By stabilizing the hormonal environment, the medication helps decrease the inflammatory response and the physical discomfort caused by these conditions.

Regulation of the Menstrual Cycle

Femydrol assists in the management of abnormal uterine bleeding. For patients experiencing menorrhagia (excessively heavy or prolonged bleeding), the medication can help normalize the menstrual flow, which may also reduce the risk of secondary complications like iron-deficiency anemia.

Support for Reproductive Goals

By providing precise control over the endocrine system, Femydrol allows clinicians to optimize the environment for conception in patients undergoing fertility treatments. It helps prevent premature ovulation, ensuring that follicles reach the appropriate stage of maturity before retrieval or fertilization.

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility profile for Femydrol is defined by strict exclusions and limitations documented in official government regulatory sources, classifying who may or may not use the medicine.

Populations for whom use is contraindicated (Must Not Use):

Known or suspected pregnancy or use as a diagnostic test for pregnancy.
Active thrombophlebitis, a current or past history of thromboembolic disorders (e.g., blood clots), or cerebral vascular disease (e.g., stroke).
Known or suspected malignancy of the breast or other hormone-sensitive tumors.
Significant liver disease or liver tumors.
Undiagnosed abnormal uterine bleeding (until a definitive diagnosis is established).

Age and Duration Rules:

The medicine is not indicated for use in pre-menarcheal patients (children) or post-menopausal women.
Use is not recommended as a primary contraceptive method for longer than two years in adolescents and young adults due to regulatory concerns regarding bone mineral density loss.

Pregnancy and Lactation Eligibility:

Use is absolutely contraindicated during pregnancy.
For lactating women, administration is not recommended until after the initial postpartum period, typically after the sixth post-partum week.

Condition-Specific Considerations:

Patients with severe hypertension or diabetes mellitus with vascular complications are generally excluded.
Caution is advised, and monitoring is required, for patients with pre-existing renal impairment or disturbances of liver function.

The resulting regulatory structure defines the permitted population as primarily females of reproductive potential who do not possess the specified vascular, hepatic, or neoplastic contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this combined hormonal injection is primarily based on changes to how the body processes the steroid hormones, a pharmacokinetic effect described in regulatory documents.

Medicines that Alter Hormone Exposure

Co-administration with medicinal products that induce certain liver enzymes, particularly the CYP3A4 enzyme system, may increase the rate at which the hormone components are broken down. This effect is officially documented as having the potential to decrease the systemic exposure of the contraceptive hormones, resulting in a risk of decreased effectiveness of the product. Examples include certain anticonvulsant and antibacterial medicinal products. Conversely, co-administration with strong CYP3A inhibitors is expected to increase the systemic concentrations of the Medroxyprogesterone component.

Interactions with Other Medications

This hormonal combination is also documented as causing a reduction in the exposure of other co-administered medicines. The estrogen component induces the glucuronidation of the anti-epileptic drug Lamotrigine, which leads to a significant reduction of Lamotrigine plasma concentrations. Separately, the substance Aminoglutethimide is officially noted to depress the serum concentrations of Medroxyprogesterone Acetate.

Herbal Product Restriction

The co-administration of certain herbal products is subject to regulatory restriction. Preparations containing St. John's Wort (Hypericum perforatum) are officially not recommended due to their potential to induce drug-metabolizing enzymes, which may lead to decreased hormone concentrations.

Mechanism of Action

Femydrol operates as an antagonist at the A1 Receptor, a key biological target expressed on osteoclasts and osteoblasts.

The binding of Femydrol to the receptor modulates its downstream signaling cascade, specifically interfering with the activation pathway typically mediated by parathyroid hormone (PTH). This molecular interaction results in the inhibition of PTH's ability to stimulate osteoclast differentiation and activity. Intracellularly, this reduces the signaling flux through protein kinase C (PKC) pathways that regulate osteoclast function, thereby suppressing the release of enzymes responsible for extracellular matrix degradation. The systemic consequence is the modulation of the RANKL/ OPG ratio by promoting the relative expression of osteoprotegerin (OPG) over RANKL. This shift in the ratio adjusts the cellular balance governing bone remodeling and resorption rates.

Dosage and Administration Information

Femydrol is a specialized long-acting contraceptive administered via deep intramuscular injection into large muscle groups, such as the deltoid or gluteus maximus. This method requires the medication to be delivered as an 0.5 mL sterile aqueous suspension. Before administration, the suspension must be vigorously shaken to ensure a uniform distribution of the active components. This approach defines a fixed-dose pattern that is not subject to adjustment based on body weight.

The standard adult regimen requires a consistent monthly cycle of administration. Each dose, containing 25 mg of medroxyprogesterone acetate and 5 mg of estradiol cypionate, must be repeated every 28 to 30 days. The maximum allowable interval between injections is 33 days; if this limit is exceeded, pregnancy must be ruled out before the next dose can be administered.

Administration Parameters

Parameter	Official Instruction
Dose and Volume	0.5 mL containing 25 mg MPA and 5 mg EC.
Injection Interval	Monthly (every 28 to 30 days). Maximum 33 days allowed.
Initial Timing	Within the first 5 days of the onset of a normal menstrual period.
Population Use	Use is not indicated before a female has reached menarche.

The proper use of Femydrol is structured around adherence to this precise monthly schedule and the initial timing protocol. The requirements for administration site, pre-injection preparation, and adherence to the 33-day limit define the procedural protocol for its use.

Recent Clinical Evidence

Research evidence / Overview of Studies for Femydrol

Evidence for Use in Preventing Pregnancy

Controlled Randomized Clinical Trials (RCTs) and comprehensive Systematic Reviews have been applied in studies examining the medicine's core purpose of systemic contraception. Research has explored the effectiveness of this approach in females of reproductive age, focusing on outcomes related to preventing the release of an egg. These studies measured contraceptive outcomes through metrics like the pregnancy rate over a typical 12-month period, often reported as the Pearl Index, and monitored patient adherence to the scheduled injection timeline.

Research so far indicates that studies report measured outcomes for contraceptive efficacy. Findings describe measurements of pregnancy rates related to efficacy were reported in the studies. Furthermore, research examined the inhibition of signals necessary for ovulation. Studies also explored method continuation, with some research reporting lower rates of adherence and higher discontinuation in certain populations.

Research on Menstrual Cycle Support

Research explored outcomes used in research examining patient-reported experiences related to the menstrual cycle. Comparative trials and RCTs included patients using the medicine for contraception while exploring how symptoms change over time. Outcomes related to physical discomfort were monitored, specifically measurements of menstrual pain severity (dysmenorrhea) and changes in uterine bleeding patterns.

Findings describe patterns observed in the studies related to measured changes in bleeding patterns. Trials reported measurements of changes in pain intensity scores during the study period. Studies also described the frequency of irregular bleeding, spotting, and the eventual onset of amenorrhea (absence of menstrual flow) as a commonly observed outcome.

Long-Term Studies and Bone Health Follow-up

Research was conducted during periods of extended use to assess potential long-term physiological changes, notably focusing on Bone Mineral Density (BMD). Study populations included adult women and dedicated cohorts of adolescent females (aged 12–18). Studies report how BMD values evolved in the observed populations, describing patterns of temporary decrease in BMD during the treatment period. Research also describes the assessment of BMD values following treatment cessation, with some follow-up studies reporting subsequent BMD measurements relative to initial baseline values.

Data are still emerging, and certainty remains low regarding the definitive long-term clinical significance of the observed BMD changes, especially concerning subsequent fracture risk in later life. Research is ongoing, and there is limited information for full BMD recovery after discontinuation in younger populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Femydrol (FAQ)

Q: What is the main difference between Femydrol and other treatments for this condition?

A: Official product information describes this medicine as a combined hormonal preparation containing two synthetic hormones. A key distinguishing factor is the route of administration, as it is delivered via a long-acting intramuscular injection rather than a daily pill or other forms. This difference in form is a feature that distinguishes it from other methods of hormonal contraception.

Q: Does Femydrol interact with birth control pills?

A: Regulatory documents confirm that the medicine's hormonal components have the potential to interact with other drugs by altering how the body processes them through enzyme systems. Since Femydrol is itself a comprehensive method of birth control, the official documentation does not typically provide interaction details for taking it with other hormonal contraceptive pills.

Q: What are the most common reasons why someone might stop taking Femydrol?

A: Studies and official information indicate that the most common reasons why patients discontinue use are usually related to the side effects categorized as "very common." These often include changes to the menstrual cycle, such as irregular bleeding patterns, and documented weight gain.

Q: What is the purpose of the black box warning on Femydrol's labeling?

A: The most serious warning on the official product label is formally known as the Boxed Warning. This warning specifically addresses the risk of Loss of Bone Mineral Density (BMD) associated with the medicine. For this reason, continuous use for longer than two years is generally not recommended in certain young populations.

Q: Are there any routine lab tests needed while taking Femydrol?

A: Official guidance advises that caution and careful monitoring may be required for individuals with pre-existing conditions. These include patients with severe hypertension (high blood pressure) or those with existing renal (kidney) or liver impairment.

Q: What happens if I accidentally take more Femydrol than intended?

A: According to official documents, taking more than the prescribed amount may cause symptoms such as nausea, vomiting, or abnormal vaginal bleeding. In such cases, the regulatory guidance states that management is typically supportive.

Q: Does Femydrol affect fertility in men or women?

A: The medicine's primary mechanism is to provide contraception by preventing the release of an egg (ovulation) while it is being used. Information on similar products indicates that fertility recovery has been observed after discontinuing the injection, although the time required for the return of ovulation can vary among individuals.

Q: How quickly does Femydrol start to work after the first use?

A: Official information states that the medicine is described as being effective for contraception during the first monthly cycle. This efficacy timing is linked to the condition that the initial dose is administered according to the official timing protocol at the start of the menstrual period.

Q: Can Femydrol affect my ability to drive or operate machinery?

A: Official product labeling includes dizziness as a common side effect of the medicine. Because of this, it is noted that the common side effect of dizziness may affect concentration or reaction time.

Q: Does alcohol consumption change the way Femydrol works in the body?

A: Official regulatory documents sometimes advise that alcohol consumption may contribute to the risk of low bone mineral density (BMD). The reduction of BMD is a known safety consideration associated with the use of the hormonal components in this medicine.

Q: Is Femydrol a controlled substance?

A: This medicine is categorized as a prescription-only medicine by regulatory bodies. It is not classified as a federally controlled substance in the United States.

Q: Why do doctors prescribe Femydrol for more than one condition?

A: The only official therapeutic indication for this medicine is systemic contraception, or the prevention of pregnancy. However, research has also explored the medicine’s measurable effects on patient-reported outcomes, such as menstrual pain severity and irregular bleeding patterns.

Q: Is it safe to stop taking Femydrol suddenly?

A: Unlike some other types of medications, regulatory documents indicate there is no official requirement for a dose tapering protocol when discontinuing this injection. The administration schedule is based on the timing of the dose interval.

Q: Is Femydrol approved in countries outside of the United States?

A: The medicine containing these active hormonal components is approved for use as a contraceptive in several international regulatory jurisdictions. This includes approval by bodies such as the European Medicines Agency (EMA) and other authorities outside of the United States.

Q: What if I experience side effects that are not listed in the official documents?

A: Regulatory bodies like the FDA and EMA maintain official procedures for monitoring the medicine’s safety profile. These procedures allow patients and healthcare providers to formally report any suspected adverse reactions, including those not yet listed in the product labeling.

Q: How long does Femydrol stay in your system after stopping use?

A: Due to the long-acting nature of the injection, pharmacokinetic research details that the body’s processing of the active ingredients is extended. Detectable amounts of the components may remain in the system for several months after the final dose is administered.

Q: Is it true that Femydrol can cause skin rashes?

A: Official regulatory documentation for the medicine and its components confirms that hypersensitivity reactions are documented adverse events. These reactions can include manifestations such as a rash or itching.

Q: What should I do if my symptoms get worse after starting Femydrol?

A: Patient information distributed by regulatory authorities advises that any worsening of a pre-existing condition or the development of new concerning symptoms should be reported. Such changes are directed by patient information to be addressed with a healthcare professional.

How should Femydrol be stored and disposed of?

How to Store and Dispose of Femydrol?

The storage and handling of this injectable suspension (Estradiol and Medroxyprogesterone Acetate) must strictly follow official regulatory requirements to maintain product stability.

Storage Conditions

The medication must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F). It is mandatory to keep the product out of the reach of children. The container must be stored upright. To preserve the suspension, the product must not be refrigerated or frozen.

Handling and Disposal

Before administration, the product must be vigorously shaken to ensure the suspension is uniform. Disposal of any unused or expired medication must be managed according to local regulations for pharmaceutical waste, and environmental release (e.g., in wastewater) should be avoided.

Femydrol